Cargando…

Multi-omics approach to precision medicine for immune-mediated diseases

Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Mineto, Fujio, Keishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325815/
https://www.ncbi.nlm.nih.gov/pubmed/34332645
http://dx.doi.org/10.1186/s41232-021-00173-8
_version_ 1783731625801023488
author Ota, Mineto
Fujio, Keishi
author_facet Ota, Mineto
Fujio, Keishi
author_sort Ota, Mineto
collection PubMed
description Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich information to clinical settings is of great social significance. For some traits such as cardiovascular diseases, attempts to apply omics datasets in clinical practice for the prediction of the disease risk have already shown promising results, although still under way for immune-mediated diseases. Multiple studies have tried to predict treatment response in immune-mediated diseases using genomic, transcriptomic, or clinical information, showing various possible indicators. For better prediction of treatment response or disease outcome in immune-mediated diseases, combining multi-layer information together may increase the power. In addition, in order to efficiently pick up meaningful information from the massive data, high-quality annotation of genomic functions is also crucial. In this review, we discuss the achievement so far and the future direction of multi-omics approach to immune-mediated diseases.
format Online
Article
Text
id pubmed-8325815
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83258152021-08-02 Multi-omics approach to precision medicine for immune-mediated diseases Ota, Mineto Fujio, Keishi Inflamm Regen Review Recent innovation in high-throughput sequencing technologies has drastically empowered the scientific research. Consequently, now, it is possible to capture comprehensive profiles of samples at multiple levels including genome, epigenome, and transcriptome at a time. Applying these kinds of rich information to clinical settings is of great social significance. For some traits such as cardiovascular diseases, attempts to apply omics datasets in clinical practice for the prediction of the disease risk have already shown promising results, although still under way for immune-mediated diseases. Multiple studies have tried to predict treatment response in immune-mediated diseases using genomic, transcriptomic, or clinical information, showing various possible indicators. For better prediction of treatment response or disease outcome in immune-mediated diseases, combining multi-layer information together may increase the power. In addition, in order to efficiently pick up meaningful information from the massive data, high-quality annotation of genomic functions is also crucial. In this review, we discuss the achievement so far and the future direction of multi-omics approach to immune-mediated diseases. BioMed Central 2021-08-01 /pmc/articles/PMC8325815/ /pubmed/34332645 http://dx.doi.org/10.1186/s41232-021-00173-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Ota, Mineto
Fujio, Keishi
Multi-omics approach to precision medicine for immune-mediated diseases
title Multi-omics approach to precision medicine for immune-mediated diseases
title_full Multi-omics approach to precision medicine for immune-mediated diseases
title_fullStr Multi-omics approach to precision medicine for immune-mediated diseases
title_full_unstemmed Multi-omics approach to precision medicine for immune-mediated diseases
title_short Multi-omics approach to precision medicine for immune-mediated diseases
title_sort multi-omics approach to precision medicine for immune-mediated diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325815/
https://www.ncbi.nlm.nih.gov/pubmed/34332645
http://dx.doi.org/10.1186/s41232-021-00173-8
work_keys_str_mv AT otamineto multiomicsapproachtoprecisionmedicineforimmunemediateddiseases
AT fujiokeishi multiomicsapproachtoprecisionmedicineforimmunemediateddiseases